Antisense-mediated exon skipping: A versatile tool with therapeutic and research applications
- 7 August 2007
- journal article
- review article
- Published by Cold Spring Harbor Laboratory in RNA
- Vol. 13 (10) , 1609-1624
- https://doi.org/10.1261/rna.653607
Abstract
Antisense-mediated modulation of splicing is one of the few fields where antisense oligonucleotides (AONs) have been able to live up to their expectations. In this approach, AONs are implemented to restore cryptic splicing, to change levels of alternatively spliced genes, or, in case of Duchenne muscular dystrophy (DMD), to skip an exon in order to restore a disrupted reading frame. The latter allows the generation of internally deleted, but largely functional, dystrophin proteins and would convert a severe DMD into a milder Becker muscular dystrophy phenotype. In fact, exon skipping is currently one of the most promising therapeutic tools for DMD, and a successful first-in-man trial has recently been completed. In this review the applicability of exon skipping for DMD and other diseases is described. For DMD AONs have been designed for numerous exons, which has given us insight into their mode of action, splicing in general, and splicing of theDMDgene in particular. In addition, retrospective analysis resulted in guidelines for AON design forDMDand most likely other genes as well. This knowledge allows us to optimize therapeutic exon skipping, but also opens up a range of other applications for the exon skipping approach.Keywords
This publication has 142 references indexed in Scilit:
- Antisense Oligonucleotide-induced Exon Skipping Across the Human Dystrophin Gene TranscriptMolecular Therapy, 2007
- The Influence of Antisense Oligonucleotide Length on Dystrophin Exon SkippingMolecular Therapy, 2007
- Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMDGene Therapy, 2006
- Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathologyNature Medicine, 2006
- Functional Analysis of 114 Exon-Internal AONs for Targeted DMD Exon Skipping: Indication for Steric Hindrance of SR Protein Binding SitesOligonucleotides, 2005
- Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotideThe Journal of Gene Medicine, 2005
- Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cellsGene Therapy, 2004
- Evidence for the widespread coupling of alternative splicing and nonsense-mediated mRNA decay in humansProceedings of the National Academy of Sciences, 2002
- Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophyThe Journal of Gene Medicine, 2002
- Listening to silence and understanding nonsense: exonic mutations that affect splicingNature Reviews Genetics, 2002